View Post

SABCS 2018: Happy and Hopeful about Less Hormone Therapy

In In The News by Barbara Jacoby

By Karuna Jaggar, Executive Director From: bcaction.org The strong response gets at how much women hate taking tamoxifen. Tamoxifen is the oldest and most common breast cancer treatment and was made more than 50 years ago. It’s cheap (at around $1 a day) and effective. Treatment with tamoxifen is usually a daily pill for five years (and up to 10 …

View Post

There is need for chemoprevention options for women with breast cancer, says GlobalData

In In The News by Barbara Jacoby

Breast cancer is the most common female cancer worldwide. Women who are at high-risk of developing the disease have few chemoprevention options and often resort to invasive prophylactic surgery. Leading data and analytics company GlobalData, feels that new non-invasive chemoprevention strategies for women who are genetically predisposed to breast cancer are sorely needed. While selective estrogen receptor modulators (SERMs) such …

Skin gel new ammunition in fight against breast cancer

In In The News by Barbara Jacoby

By Caelainn Hogan From: washingtonpost.com A gel containing the drug tamoxifen and applied to the skin was as effective in reducing the growth of breast cancer cells in women with noninvasive cancer as the pill form of the medication — and it caused fewer side effects, according to a new study. The paper, published Tuesday in Clinical Cancer Research, a …

Twice the Tamoxifen Backed for Breast Cancer Patients

In In The News by Barbara Jacoby

By:  Hope T. Jackson, MD From: abcnews.go.com One of the top cancer groups in the U.S. is urging breast cancer patients to take the drug tamoxifen for 10 years after treatment with surgery, chemo or radiation – effectively doubling the previously recommended five years on the drug. Tamoxifen targets the hormones estrogen and progesterone, which are important in the development …

Proteomics can improve breast cancer treatmen

In In The News by Barbara Jacoby

From medicalxpress.com Researchers at Karolinska Institutet in Sweden have identified a protein that could help physicians decide what type of therapy patients with hormone driven breast cancer should go through. In a study, published in Nature Communications, they show that high levels of a protein called retinoic acid receptor alpha (RARA) in breast tumors can be linked to an insufficient …

Risk Of Breast Cancer Recurrence After Tamoxifen Treatment Predicted By Biomarker

In In The News by Barbara Jacoby

From Medical News Today A biomarker reflecting expression levels of two genes in tumor tissue may be able to predict which women treated for estrogen-receptor (ER)-positive breast cancer should receive a second estrogen-blocking medication after completing tamoxifen treatment. In their report published online in the Journal of the National Cancer Institute, Massachusetts General Hospital (MGH) Cancer Center investigators describe finding …